FONDAZIONE
PER LA RICERCA FARMACOLOGICA
GIANNI BENZI
ONLUS

COVID-19 treatments under evaluation

The **Human Medicines Committee (CHMP) at EMA** is evaluating a marketing authorisation application for the following COVID-19 treatments

Treatment	Developer	Description	EMA evaluation process	Start of evaluation	PIP number	More information
Paxlovid (PF-07321332/ritonavir)	Pfizer	Paxlovid is an oral antiviral medicine that reduces the ability of SARS-CoV-2 to multiply in the body. The active substance PF-07321332 blocks the activity of an enzyme needed by the virus to multiply. Paxlovid also contains a low dose of ritonavir (a protease inhibitor), which slows the breakdown of PF-07321332, enabling it to remain longer in the body at levels that affect the virus	Rolling review	16/12/2021	-	https://www.ema.europa.eu/en/news/ema-starts-review-paxlovid-treating-patients-covid-19
Lagevrio (molnupiravir)	Merck Sharp & Dohme and Ridgeback Biotherapeutics	Lagevrio is an oral antiviral medicine that reduces the ability of SARS-CoV-2 to multiply in the body, by introducing mutations in the RNA of SARS-CoV-2 during replication in a way that impairs the ability of the virus to multiply	Marketing authorisation evaluation	23/11/2021	-	https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-lagevrio-molnupiravir-treating-patients-covid-19

Treatment	Developer	Description	EMA evaluation process	Start of evaluation	PIP number	More information
Evusheld (tixagevimab/cilgavimab)	AstraZeneca AB	This medicine is made of tixagevimab and cilgavimab, two monoclonal antibodies designed to attach to the Spike protein of SARS-CoV-2 at two different sites. By attaching to the Spike protein, the medicine is expected to stop the virus from entering the body's cells and causing infection. Because the antibodies attach to different parts of the protein, using them in combination may be more effective than using either alone	Rolling review	14/10/2021	-	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-evusheld-tixagevimab-cilgavimab
Olumiant	Eli Lilly Nederland B.V.	Olumiant is an immunosuppressant. It is currently authorised for use in adults with moderate to severe rheumatoid arthritis or atopic dermatitis (eczema). Its active substance, baricitinib, blocks the action of enzymes Janus kinases that	Marketing authorisation evaluation	29/04/2021	EMEA-001220-PIP07-20	https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-olumiant-hospitalised-covid-19-patients-requiring-supplemental-oxygen

Treatment	Developer	Description	EMA evaluation process	Start of evaluation	PIP number	More information
		play an important role in immune processes that lead to inflammation. This could also help reduce the inflammation and tissue damage associated with severe COVID-19 infection				
Monoclonal antibodies bamlanivimab and etesevimab	Eli Lilly	Bamlanivimab and etesemivab are monoclonal antibodies that have been designed to attach to the Spike protein of SARS-CoV-2 at two different sites. When they attach to the Spike protein, the virus cannot enter the body's cells. Because the antibodies attach to different parts of the protein, using them in combination may have a greater effect than using either alone	Withdrawn from rolling review on 29/10/2021	11/03/2021	• EMEA-002952-PIP01-21 • EMEA-002966-PIP01-21	• https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesemivab-covid-19 • https://www.ema.europa.eu/en/news/ema-ends-rolling-review-antibodies-bamlanivimab-

Treatment	Developer	Description	EMA evaluation process	Start of evaluation	PIP number	More information
						etesevimab-covid-19-following-withdrawal-lilly